Statin therapy in lupus-mediated atherogenesis: two birds with one stone?

van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS
Ann Rheum Dis. 2011 70 (2): 245-8

PMID: 21068103 · PMCID: PMC3306212 · DOI:10.1136/ard.2010.133827

The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.

MeSH Terms (7)

Animals Atherosclerosis Disease Models, Animal Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Lupus Erythematosus, Systemic Mice

Connections (1)

This publication is referenced by other Labnodes entities: